On July 30, 2019, the Senate Finance Committee passed the Prescription Drug Pricing Reduction Act (PDPRA) of 2019. The bill would have dramatic implications to manufacturers spanning Medicare ASP + Reimbursement, Medicare Coverage GAP Liabilities and Medicaid, to name a few. Hear Akara’s thoughts on what are some of the implications to life sciences manufacturers…Hint: they are pretty big.